Navigation Links
New Drug Being Tested for Pancreatic Cancer
Date:4/15/2009

Lab findings show potential for use alone or in combination, scientist says,,

WEDNESDAY, April 15 (HealthDay News) -- An experimental drug appeared to reduce pancreatic cancer growth in laboratory tests, according to researchers from the drug's maker, Amgen.

Called AMG 479, the drug is designed to inhibit the activity of insulin-like growth factors IGF-1 and IGF-2.

"We know that insulin-like growth factors play a role in cancer development, particularly in mediating cell survival," Pedro J. Beltran, a principal scientist in oncology research at Amgen, said in a news release from the American Association for Cancer Research. "This is the first drug that specifically targets the receptor for these growth factors without cross-reacting with the closely related insulin receptor."

Beltran and his fellow researchers found that AMG 479 bound to IGF-1R and blocked both IGF-1 and IGF-2 binding factors 1 and 2. The drug also completely inhibited ligand-induced activation in some growth factors, resulting in decreased pancreatic cell viability. The drug achieved an 80 percent inhibition rate of tumor growth and receptor expression, according to the researchers.

The findings appear in the current issue of Molecular Cancer Therapies.

"These data clearly show that AMG 479 is a clinical candidate for pancreatic cancer therapy, either alone or in combination with gemcitabine," Beltran said.

Gemcitabine is the only available treatment for pancreatic cancer, but the researchers said that it has yet to show a survival benefit.

AMG 479 is now being tested in nine separate phase II studies of various cancer types.

An estimated 200,000 people are diagnosed each year with pancreatic cancer, according to background information in the news release. Less than 4 percent live more than five years, it said, making pancreatic cancer one of the deadliest cancers.

More information

The American Cancer Society has more about pancreatic cancer.



-- Robert Preidt



SOURCE: Amgen, news release, April 14, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Adult Well-Being Services Offers Valuable Resources for Caregivers
2. Don't Sacrifice Your Well-being in a Discount Destination
3. On Being a Scientist: A Guide to Responsible Conduct in Research, third edition
4. Many Americans Fear Being Diagnosed With Diabetes
5. Pitt vaccine to prevent colon cancer being tested in patients
6. Employee cardiovascular health relates to psychological well-being
7. Video: CLARITIN Partners with NASCAR Driver Carl Edwards to Educate Motorists on the Importance of Being Clear to Drive(SM)
8. Childrens Bedding Naturally Enhances Emotional Well-being
9. Nurse practitioners dont realize how much their prescribing is being influenced by drug marketing
10. Patients being discharged against medical advice
11. Patients Being Discharged Against Medical Advice
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Drug Being Tested for Pancreatic Cancer
(Date:2/18/2017)... (PRWEB) , ... February 17, 2017 , ... ... , drvallecillos.com , Beverly Hills plastic surgeon Dr. Glenn Vallecillos ... cells. , Dr. Vallecillos says, "Traditionally, plastic surgery has been centered around that ...
(Date:2/17/2017)... , ... February 17, 2017 , ... Smiles by Seese ... Center in Davidson, NC. Dr. Brian Seese leads the practice as a skilled and ... under one roof. Smiles by Seese serves patients of all ages with excellence in ...
(Date:2/17/2017)... ... February 17, 2017 , ... For the ... management solution to the exhibit floor for the 2017 HIMSS Conference & ... From Feb. 19–23, 2017, more than 40,000 healthcare industry professionals are expected at ...
(Date:2/17/2017)... ... 2017 , ... Qualis Health, one of the nation's leading ... DecisionHealth Platinum Awards in recognition of its innovative healthcare management programs that are ... award categories, highlighting four of the organization’s current programs:, , ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting attended CHI's ... facets of clinical trial planning and management. Pharmica discussed the importance of effective ... addition, attendees stopping by Pharmica’s booth were able to demo its cloud-based ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... , Feb. 17, 2017  Noble Capital Markets ... ESSA Pharma Inc. (Nasdaq: EPIX ). The ... Kumar Raja , PhD. ESSA Pharmaceuticals ... castration resistant prostate cancer (CRPC). Its lead compound EPI-506, ... the amino-terminal domain of the androgen receptor, thereby has ...
(Date:2/16/2017)... 16, 2017 Research and Markets has ... Medical Device Technologies" report to their offering. ... Traditional medical ... general instruments, non-drug coated implantables, large endoscopes, needle based drug ... over the last two to three decades for the treatment ...
(Date:2/16/2017)... DaVita Inc. (NYSE: DVA ) today announced results ... Net income attributable to DaVita Inc. for the ... or $0.80 per share and $880 million, or $4.29 per ... DaVita Inc. for the quarter and year ended December 31, ... or $0.98 per share, and $789 million, or $3.85 per ...
Breaking Medicine Technology: